We are buying 25 shares of Danaher , at roughly $250.48 apiece. Following Tuesday's trade, Jim Cramer's Charitable Trust will be own 520 shares of DHR, increasing its weighting in the portfolio to 4.58% from 4.37%. Our purchase of additional shares of the life-sciences-and-medical-diagnostics firm Danaher on Tuesday is on the smaller side because we are hesitant to put too much money to work in a volatile market.
Our approach amid the August pullback has been to purchase high-quality companies that have reported strong quarters and provided positive forward guidance this earnings season. Danaher is a slight deviation from the plan because the company reported only a modest earnings beat and slightly cut its full-year outlook due to ongoing weakness in the bioprocessing market.